Running title: PICH targets SUMOylated chromosomal proteins 15 16 Summary Statement 17 Polo-like kinase interacting checkpoint helicase (PICH) interacts with SUMOylated proteins to mediate 18 proper chromosome segregation during mitosis. The results demonstrate that PICH promotes redistribution 19 of SUMOylated chromosomal proteins, including Topoisomerase IIα, and that function requires PICH 20 translocase activity. 30 SENP Sentrin-specific protease 31 PIAS Protein inhibitor of activated STAT 32 SIM SUMO-interacting-motif 33 34 Abstract 37 Polo-like kinase interacting checkpoint helicase (PICH) is a SNF2 family DNA translocase and is a Small 38 Ubiquitin-like modifier (SUMO) binding protein. Despite that both translocase activity and SUMO-binding 39 ability are required for proper chromosome segregation, how these two activities function to mediate 40 chromosome segregation remains unknown. Here, we show that PICH specifically promotes redistribution 41 of SUMOylated proteins like SUMOylated TopoisomeraseIIα (TopoIIα) on mitotic chromosomes. 42 Conditional depletion of PICH using the Auxin Inducible Degron (AID) system resulted in the retention of 43 SUMOylated chromosomal proteins, including TopoIIα, indicating that PICH functions to redistribute these 44 proteins. Replacement of endogenous PICH with exogenous PICH mutants showed that PICH translocase 45 activity is required for SUMOylated protein redistribution. In vitro assays showed that PICH specifically 46 regulates SUMOylated TopoIIα activity using its SUMO-binding ability. Taken together, we propose a 47 novel function of PICH in remodeling SUMOylated chromosomal proteins to ensure faithful chromosome 48 segregation. 49 50
.
54
Compared to the well-described regulation of Cohesin (Morales and Losada, 2018) , the regulation of 55 catenated DNA cleavage by DNA TopoisomeraseIIα (TopoIIα) is not fully understood despite its critical 56 role in chromosome segregation. ATP-dependent DNA decatenation by TopoIIα takes place during the 57 metaphase-to-anaphase transition and this allows for proper chromosome segregation (Shamu and Murray, 58 1992, Wang et al., 2010) . Failure in resolution of catenanes by TopoIIα leads to the formation of 59 chromosome bridges, and ultra-fine DNA bridges (UFBs) to which PICH localizes (Spence et al., 2007) .
60
PICH is a SNF2 family DNA translocase (Baumann et al., 2007 , Biebricher et al., 2013 , and its binding to 61 UFBs recruits other proteins to UFBs (Chan et al., 2007 , Hengeveld et al., 2015 . In addition to the role in 62 UFB binding during anaphase, PICH has been shown to play a key role in chromosome segregation at the 63 metaphase to anaphase transition (Baumann et al., 2007 , Nielsen et al., 2015 , Sridharan and Azuma, 2016 .
64
Previously, we demonstrated that PICH binds SUMOylated proteins using its three SUMO 65 interacting motifs (SIMs) (Sridharan et al., 2015) . PICH utilizes ATPase activity to translocate DNA similar 66 to known nucleosome remodeling enzymes (Whitehouse et al., 2003) , thus it is a putative remodeling 67 enzyme for chromosomal proteins. But, the nucleosome remodeling activity of PICH was shown to be 68 limited as compared to established nucleosome remodeling factors (Ke et al., 2011) . Therefore, the target 69 of PICH remodeling activity has not yet been determined. Importantly, both loss of function PICH mutants 70 in either SUMO-binding activity or translocase activity showed chromosome bridge formation (Sridharan 71 and Azuma, 2016) , suggesting that both of these activities cooperate to accomplish proper chromosome 72 segregation albeit the molecular mechanism linking these two functions is unknown. Previous studies 73 demonstrated that proper regulation of mitotic chromosomal SUMOylation is required for faithful 74 chromosome segregation (Cubeñas-Potts et al., 2013; Díaz-Martínez et al., 2006; Nacerddine et al., 2005) .
75
Studies using C. elegans demonstrated the dynamic nature of SUMOylated proteins during mitosis and its 76 critical role in chromosome segregation (Pelisch et al., 2014) . Several SUMOylated chromosomal proteins 77 were identified for their potential role in chromosome segregation, for example; TopoIIα, CENP-A, CENP-78 E, FoxM1, and Orc2 (Bachant et al., 2002; Huang et al., 2016; Ohkuni et al., 2018; Schimmel et al., 2014;  79 Zhang et al., 2008) . Because PICH is able to specifically interact with SUMO moieties (Sridharan et al., TopoIIα has been shown to functionally interact with PICH. PICH-knockout cells have increased sensitivity 83 to ICRF-193, a potent TopoII catalytic inhibitor, accompanied with increased incidence of chromosome 84 bridges, binucleation, and micronuclei formation (Kurasawa and Yu-Lee, 2010 , Nielsen et al., 2015 , Wang 85 et al., 2008 . stalls TopoIIα at the last step of the strand passage reaction (SPR) in which two 86 DNA strands are trapped within the TopoIIα molecule without DNA strand breaks (Patel et al., 2000 , Roca 87 et al., 1994 . In addition to that specific mode of inhibition, has been shown to increase 88 SUMOylation of TopoIIα (Agostinho et al., 2008; Pandey et al., 2020) . Because PICH has SUMO binding 89 ability, it is possible that increased SUMOylation of TopoIIα contributes to interaction with PICH under 90 no 
110
We previously reported that PICH utilized its SIMs for proper chromosome segregation and for its 111 mitotic chromosomal localization (Sridharan and Azuma, 2016 (Agostinho et al., 2008; Pandey et al., 2020) . We utilized these two contrasting inhibitors to assess whether 118 TopoIIα inhibition and/or SUMOylation changes PICH distribution on mitotic chromosomes. DLD-1 cells 119 were synchronized in prometaphase, and mitotic cells were collected by mitotic shake off then 120 chromosomes were isolated. To assess the effects of the TopoII inhibitors specifically during mitosis, the 121 inhibitors were added to cells after mitotic shake off. Consistent with previous reports (Agostinho et al., 122 2008; Pandey et al., 2020) , Western blot analysis of isolated chromosomes showed that treatment with 123 ICRF-193 significantly increased the overall SUMO2/3 modification of chromosomal proteins including 124 SUMOylated TopoIIα (marked by red asterisks in Figure 1A ). Intriguingly, when PICH levels on mitotic 125 chromosomes were measured they were found to be significantly increased upon treatment with 
126
In contrast, Merbarone did not increase the level of these proteins on the chromosomes suggesting that there 127 is a specificity of ICRF-193 which causes increased levels of PICH and SUMOylation of TopoIIα ( Figure   128 1A).
129
To investigate the localization of PICH on mitotic chromosomes under treatment with ICRF-193, 130 mitotic cells were subjected to immunofluorescence staining. Synchronized cells were collected by mitotic 131 shake off, treated with inhibitors, then plated onto fibronectin coated coverslips. Cells were fixed after a 132 20-minute incubation and subjected to immunofluorescent staining. As seen in Western blot analysis, 133 increased intensity of SUMO2/3 foci were enriched on the chromosomes, where they overlapped with 134 TopoIIα foci upon . Although, TopoIIα signal changed 135 slightly under Merbarone treatment, no enrichment of SUMO2/3 foci were observed ( Figure 1B) . A novel 136 observation showed that PICH foci were also found to be enriched on the chromosomes where they 137 overlapped with SUMO2/3 foci upon ICRF-193 treatment. But, treatment with Merbarone did not affect 138 PICH localization ( Figure 1C ). These data show that treatment with ICRF-193, but not Merbarone, causes 139 increased TopoIIα SUMOylation and enrichment of PICH and SUMO2/3 foci on the chromosomes.
141
Mitotic SUMOylation is required for PICH enrichment in ICRF-193 treated cells.
142
Although results obtained from inhibiting TopoIIα suggest that increased SUMOylation plays a 143 critical role in PICH enrichment, the distinct effects of the different inhibitor treatments, for example 144 differences in TopoII conformation, could also play a role. To determine if mitotic SUMOylation is critical 145 for PICH enrichment in ICRF-193 treated cells we developed a novel method to inhibit mitotic 146 SUMOylation in cells. First, we generated a fusion protein, called Py-S2, which consists of the N-terminal 147 region of human PIASy , and the SENP2-catalytic domain (required for 148 deSUMOylation) (Reverter, David, 2004; Sridharan et al., 2015) . The N-terminal 149 region of PIASy localizes to mitotic chromosomes, in part, via its specific interaction with the RZZ (Rod-150 Zw10-Zwilch) complex . Thus, the fusion protein is expected to bring 151 deSUMOylation activity where mitotic SUMOylation occurs on chromosomes by recruitment of PIASy via 152 its N-terminal region. As a negative control, we substituted a cysteine to alanine at position 548 of SENP2 153 (called Py-S2 Mut) to create a loss of function mutant (Reverter, David, 2006 , 2004 (Figure 2A ). The 154 activity of the recombinant fusion proteins on chromosomal SUMOylation was verified in Xenopus egg 155 extract (XEE) assays (Supplemental Figure S1 ). As predicted, addition of the Py-S2 protein to XEE 156 completely eliminated mitotic chromosomal SUMOylation. To our surprise, the Py-S2 Mut protein 157 stabilized SUMOylation of chromosomal proteins, thus acting as a dominant negative mutant against 158 endogenous deSUMOylation enzymes. To express the fusion proteins in cells, we created inducible 159 expression cell lines using the Tetracycline inducible system (Supplemental Figure S2 ) (Natsume et al., 160 2016) . We utilized CRISPR/Cas9 genome editing to integrate each of the fusion genes into the human H11 161 (hH11) safe harbor locus (Ruan et al., 2015; Zhu et al., 2014) in DLD-1 cells.
162
To test whether the novel Py-S2 fusion protein worked as expected, cells were synchronized, and 163 doxycycline was added after release from a Thymidine block. After treatment with ICRF-193, 164 chromosomes were isolated and subjected to Western blot analysis. The Py-S2 expressing cells had nearly 165 undetectable levels of chromosomal SUMOylation as well as SUMOylated TopoIIα ( Figure 2B ).
166
Intriguingly in Py-S2 expressing cells, PICH levels were no longer affected by 167 suggesting that the response of PICH to ICRF-193 depends on the cell's ability to SUMOylate chromosomal 168 proteins including TopoIIα ( Figure 2B ).
169
To determine how deSUMOylation affects PICH and TopoIIα distribution, Py-S2 expressing 170 mitotic cells were stained. Immunofluorescent analysis of Py-S2 expressing cells reiterated what was 171 observed in Western blot analysis. Even under ICRF-193 treatment, Py-S2 expressing cells had nearly 172 undetectable levels of SUMO2/3 and PICH ( Figure 2C , D +Dox panels). But, TopoIIα signals remained 173 unaffected, in agreement with our previous observations in XEE assays, which showed that TopoIIα 174 localization is independent of SUMOylation (Azuma et al., 2005) (Figure 2E ).
175
The role of SUMOylation in the enrichment of PICH on mitotic chromosomes is further supported 176 by the Py-S2 Mut expressing cells. Western blot analysis of mitotic chromosomes expressing Py-S2 Mut 177 revealed slightly increased levels of overall SUMOylation as well as SUMOylated TopoIIα in the absence 178 of ICRF-193 ( Figure 3A ). This suggests that a similar stabilization of SUMOylation occurs in cells as was 179 observed in the XEE assays, albeit with less penetrance. PICH levels were also slightly increased in the Py-180 S2 Mut expressing cells in the absence of ICRF-193 ( Figure 3A ). This slight increase of both PICH and 181 SUMO2/3 seen in Western blots was even more apparent with immunofluorescence analysis. In the absence 182 of ICRF-193, Py-S2 Mut expressing cells had increased signals of PICH and SUMO2/3 on the 183 chromosomes ( Figure 3B , C comparing DMSO/-Dox and DMSO/+Dox). Similar to Figure 2E , TopoIIα 184 localization and signal intensity did not change upon Py-S2 Mut expression ( Figure 3D ). In all, these data 185 reinforce the indication that the enrichment of PICH foci on mitotic chromosomes in ICRF-193 treated cells 186 is dependent on increased SUMOylation.
188
Increased PICH levels observed in ICRF-193 treatment lost upon TopoIIα depletion.
189
Since increasing mitotic SUMOylation enriches PICH on the chromosomes, we tested whether the 190 PICH response to ICRF-193 is due to TopoIIα SUMOylation. To accomplish this, we generated a mAID-191 TopoIIα cell line, which enables rapid and complete elimination of TopoIIα in the presence of auxin 192 (Natsume et al., 2016 , Nishimura et al., 2009 . First, we established a cell line that has an integration of an 193 auxin-dependent Ubiquitin E3 ligase, OsTIR1 gene, at the promoter of a housekeeping ( Figure 4A ). Notably, ΔTopoIIα cells treated with ICRF-193 showed no changes 206 in PICH levels on the chromosomes. This suggests that increased levels of PICH seen in 207 treatment is a SUMOylated TopoIIα-dependent response ( Figure 4A ). Immunofluorescent analysis of 208 ΔTopoIIα cells showed a clear reduction of PICH foci even in the presence of ICRF-193 ( Figure 4B ). In 209 ΔTopoIIα cells, SUMO2/3 foci were no longer increased at the centromere (marked by CENP-C) in 210 response to ICRF-193 ( Figure 4C ). These results suggest that TopoIIα SUMOylation caused by 211 critically contributes to the enrichment of PICH foci on chromosomes.
213
Loss of PICH leads to enrichment of SUMOylated proteins at mitotic centromeres.
214
So far, the results indicate that PICH targets SUMOylated chromosomal proteins, mainly 215 SUMOylated TopoIIα, in ICRF-193 treated cells. Because the ability of PICH to interact with SUMO via 216 its SUMO-interacting motifs is required for proper chromosome segregation, we wished to determine if 217 PICH is required for regulating distribution of SUMOylated chromosomal proteins. To examine this, 218 mAID-PICH cells were generated as described above for TopoIIα. After auxin was added to the cells for 6 219 hours, PICH levels became undetectable by Western blot and immunofluorescent analysis (Supplemental 220 Figure S5A -E). To deplete PICH, auxin was added to the cells after release from a Thymidine block, then 221 mitotic cells were collected by mitotic shake off. Isolated chromosomes were then subjected to Western 222 blot analysis. Intriguingly, ΔPICH control cells showed a significant increase in SUMOylated TopoIIα 223 compared to -Auxin cells, shown by the appearance of a second upshifted band marked by an asterisk 224 ( Figure 5A ). This suggests that PICH is involved in the reduction of SUMOylated TopoIIα on 225 chromosomes. Immunofluorescent staining further supported this novel role of PICH. In agreement with 226 the Western blot results analysis of ΔPICH cells showed an enrichment of TopoIIα signal at the centromere 227 in both control and ICRF-193 treated cells ( Figure 5B 
236
To identify which function of PICH is required for the redistribution of SUMOylated proteins 237 including TopoIIα, we created a PICH-replacement cell line by combining mAID-mediated PICH depletion 238 and inducible expression of exogenous PICH mutants. The mAID-PICH cells had CRISPR/Cas9 targeted 239 integration of either Tet-inducible WT PICH-mCherry, an ATPase dead mutant (K128A-mCherry), or non-240 SUMO interacting form of PICH (d3SIM-mCherry) into the CCR5 safe harbor locus (Papapetrou and 241 Schambach, 2016) . After clonal isolation and validation (Supplemental Figure S6A -C), PICH-mCherry 242 expression was tested in asynchronous cells by treating with auxin and doxycycline for 14 hours, and the 243 whole cell lysates were used for Western blot analysis. Although the expression level of the exogenous 244 proteins was variable, we were able to replace endogenous PICH with exogenous PICH ( Figure 6A ). We 245 did observe variation of mCherry expression within each clonal isolate (Supplemental figure S6D ) and this 246 may explain the variation in expression levels observed in Western blot analysis. The PICH-replacement 247 for mitotic cell analysis was achieved by incubating cells with auxin or auxin and doxycycline for 22 hours 248 before mitotic shake off. The mitotic cells were treated with DMSO (control) and ICRF-193 then mitotic 249 chromosomes were isolated. Western blot analysis was performed to determine how translocase activity 250 and SIMs contribute to PICH binding to mitotic chromosomes ( Figure 6B ). The PICH WT-mCherry was 251 observed to have a similar response to ICRF-193 as endogenous PICH, showing increased binding with 252 ICRF-193 treatment. The K128A mutant also showed increased binding under ICRF-193 treatment. In 253 contrast, the d3SIM mutant could not bind to chromosomes, consistent with our previous observations 254 (Sridharan and Azuma, 2016) .
255
To further examine how the PICH mutants affect localization of TopoIIα and SUMO2/3, 256 immunofluorescent analysis of prometaphase cells was performed. PICH WT-mCherry showed the same 257 staining patterns as endogenous PICH and its response to ICRF-193 was similar to Figure 1 . Both SUMO2/3 258 and TopoIIα staining was consistent with that seen in Figure 1 ( Figure 6C ), further validating that mCherry 259 tagged exogenous PICH functions the same as endogenous PICH. When the K128A mutant, which cannot 260 translocate on DNA, was expressed in both control and ICRF-193 treated cells, strong mCherry foci were 261 observed on the chromosomes. Importantly, these foci overlap with SUMO2/3 foci ( Figure 6D ). This 262 suggests that the PICH K128A mutant interacts with SUMOylated targets but due to its inability to 263 translocate remains stably associated with the chromosomes where the SUMOylated proteins are located.
264
TopoIIα signals were enriched on the chromosomes, where signals had increased intensity and were more 265 punctate than those in Figure 6C 
299
To determine which activity of PICH is required for inhibiting SUMOylated TopoIIα decatenation 300 activity, we utilized a PICH mutant that has defects in either the SUMO-binding ability (PICH-d3SIM) or 301 in translocase activity (PICH-K128A) ( Figure 8A ) (Sridharan et al., 2016) . If PICH/SUMO interaction is 302 critical for inhibiting the decatenation activity of SUMOylated TopoIIα, the PICH-d3SIM mutant would 303 lose its inhibitory function. In addition, we also expect that the PICH translocase activity deficient (PICH- 
333
SUMOylation has been shown to play a role in complex assembly by mediating SUMO/SIM 334 interactions (Guzzo et al., 2012; Lin et al., 2006; Matmati et al., 2018; Pelisch et al., 2017) . It has been (Nielsen et al., 2015) . In contrast to that role, PICH binding to SUMOylated TopoIIα has different 
386
These novel findings lead to a more mechanistic understanding of the interaction between 387 SUMOylated TopoIIα and PICH and provide insight into why PICH knockout cells were found to be 388 sensitive to . PICH can increase TopoIIα decatenation activity in vitro and that helps to resolve 389 tangled DNA during anaphase (Nielsen et al., 2015) . In addition, recent studies indicate that the translocase 390 activity of PICH can be used to control the supercoiling status of DNA together with Topoisomerase IIIα 391 (Bizard et al., 2019) . This increased supercoiling of DNA provides a more suitable substrate for TopoIIα 392 and thus increases its decatenation activity. Both models can explain how PICH promotes decatenation on 393 tangled DNA at centromeres to prevent UFB formation or resolve existing UFBs by stimulating TopoIIα 394 activity. One unanswered question is how ICRF-193 mediated stalled TopoIIα is removed to prevent the 395 formation of chromosome bridges. ICRF-193 treatment is known to induce a closed clamp conformation 396 of TopoIIα with both detangled DNA strands bound within it (Morris et al., 2000; Roca et al., 1994) . It is 397 interesting to hypothesize from our current study that PICH SUMO-binding ability and translocase activity 398 are able to recognize and bind SUMOylated TopoIIα and remove it from DNA. Analysis of PICH function 399 using a TopoIIα-replaced cell line, utilizing the same methodology as the PICH mutant cell lines, will 400 provide insight for this model. Recently, we demonstrated that SUMOylation of TopoIIα plays a critical 401 role in controlling the progression of mitosis. ICRF-193 treatment resulted in a mitotic arrest in cells that 402 requires SUMOylated TopoIIα and subsequent Aurora B activation (Pandey et al., 2020) cDNA were subcloned into a pPIC 3.5K vector in which calmodulin-binding protein CBP-T7 tag sequences 452 were inserted as previously described (Ryu et al., 2010b, Sridharan and Azuma, 2016) . All mutations in 453 the plasmids were generated by site-directed mutagenesis using a QuikChangeII kit (Agilent) according to 454 manufacturer's instructions. All constructs were verified by DNA sequencing.
456
Recombinant protein expression and purification, and preparation of antibodies
457
Recombinant TopoIIα and PICH proteins were prepared as previously described (Ryu et al., 2010b, 458 Sridharan and Azuma, 2016) . In brief, the pPIC 3. dnUbc9, and SUMO paralogues were expressed in Rosetta2(DE3) and purified as described previously 475 (Ryu et al., 2010a) .
476
To generate the antibody for human PICH, the 3'end (coding for amino acids 947~1250) was amplified 
543
To establish AID cell lines, as an initial step, the Oryza sativa E3 ligase (OsTIR1) gene was inserted into 544 the 3' end of a housekeeping gene, RCC1, using CRISPR/Cas9 system in the DLD-1 cell line. The RCC1 545 locus was an appropriate locus to accomplish the modest but sufficient expression level of the OsTIR1 546 protein so that it would not induce a non-specific degradation without the addition of Auxin 547 (Supplemental Figure S3 ). We then introduced DNA encoding for AID-3xFlag tag into the TopoIIα or 
574
The following primary antibodies were used for Western blotting: Rabbit anti-Xenopus TopoIIα (1:10,000),
575
Rabbit anti-Xenopus PARP1 (1:10,000), Rabbit anti-SUMO2/3 (1:1,000) (all prepared as described 576 previously (Ryu et al., 2010a) ), anti-Histone H3 (#14269, Cell Signaling). 
578

Preparation of mitotic cells and chromosome isolation
13
The following primary antibodies were used for Western blotting: Rabbit anti-PICH (1:1,000), Rabbit anti-597 TopoIIα (1:20,000) (both are prepared as described above), Rabbit anti-SUMO2/3 (1:1,000), Rabbit anti-598 Histone H2A (1:2,000) (#18255, Abcam), Rabbit anti-Histone H3 (1:2,000) (#14269, Cell Signaling),
599
Rabbit anti-PIASy (1:500) (as described in (Azuma et al., 2005) 
621
The following primary antibodies were used for staining: Rabbit anti-PICH 1:800, Rabbit anti-human 622 TopoIIα 1:1000 (both are prepared as described above), Mouse anti-human TopoIIα 1:300 (#Ab 189342, 623 Abcam), Mouse anti-SUMO2/3 (#12F3, Cytoskeleton Inc), Guinea Pig anti-SUMO2/3 (1:300) (prepared 624 as previously described , and Rat anti-RFP (#RMA5F8, Bulldog Bio Inc).
626
Statistical analysis 627 All statistical analyses were performed with either 1-or 2-way ANOVA, followed by the appropriate post-628 hoc analyses using GraphPad Prism 8 software.
630
Animal use 631 For XEE assay, frog eggs were collected from a mature female Xenopus laevis, and sperm was obtained 
Figure 6. Translocase function of PICH is necessary for redistribution of SUMOylated proteins and SUMOylated TopoIIα on mitotic chromosomes. (A)
DLD-1 cells with endogenous PICH tagged with a mAID and exogenous PICH mCherry mutants were treated with auxin or auxin and doxycycline for 14 hours. Whole cell lysates were subjected to Western blotting with indicated antibodies. (B) DLD-1 cells with endogenous PICH tagged with a mAID and exogenous PICH mCherry mutants were treated with auxin or auxin and doxycycline for 22 hours. Mitotic chromosomes were isolated and subjected to Western blotting with indicated antibodies. p values for comparison among three experiments were calculated. ns: not significant; **: p < 0.01. (C) WT PICH mCherry mitotic cells were fixed and stained with antibodies against: SUMO2/3 (green), TopoIIα (green), mCherry (red). DNA was stained with DAPI (blue). Scale bar = 11μm. (D) K128A PICH mCherry mitotic cells were fixed and stained with antibodies against: SUMO2/3 (green), TopoIIα (green), mCherry (red). DNA was stained with DAPI (blue). Scale bar = 11μm. (E) d3SIM PICH mCherry mitotic cells were fixed and stained with antibodies against: SUMO2/3 (green), TopoIIα (green), mCherry (red). DNA was stained with DAPI (blue). Scale bar = 11μm. SUMOylation plays a critical role in mitotic regulation and timing, this is due in part by regulating the activity and mediating binding of critical proteins. During mitosis proteins become SUMOylated and PICH recognizes and binds these proteins using its three SUMO interacting motifs, then using its translocase activity it redistributes SUMOylated proteins on the chromosomes and this enables proper chromosome segregation. Without PICH we see an accumulation of SUMOylated proteins on the chromosomes. PICH without translocase activity also shows this similar accumulation of SUMOylated proteins on the chromosomes.
Supplemental Figure S1 . Testing SUMO modulating proteins in the Xenopus laevis egg extract system. (A) Recombinant Py-S2 or Py-S2 Mut proteins were added to Xenopus laevis egg extract upon induction of mitosis, and the chromosomes were isolated. Chromosome samples were subjected to Western blotting with anti-SUMO2/3 antibody. (B) Chromosome samples in A were subjected to Western blotting with anti-Xenopus TopoIIα antibody to detect both TopoIIα (~160kDa) and SUMOylated TopoIIα (marked with red asterisks), and anti-Xenopus PARP1 antibody to detect both PARP1 (~100kDa) and SUMOylated PARP1 (marked with red asterisks). Anti-histone H3 antibody was used as a loading control. 30nM of Py-S2 protein was sufficient to eliminate chromosomal SUMOylation, which is the equivalent concentration of endogenous PIASy protein in XEE, suggesting that the Py-S2 effectively deSUMOylates SUMOylated chromosomal proteins at a physiologically relevant concentration. Note that the concentration of dnUbc9 required for complete inhibition of chromosomal SUMOylation is 5µM in XEE, which is not within the physiological range and is difficult to induce a high expression level of dnUbc9 in cells. Addition of the Py-S2 C548A mutant (Py-S2 Mut) increased SUMO2/3 modification in chromosomal samples, including both TopoIIα SUMOylation and PARP1 SUMOylation. This suggests that the Py-S2 Mut acts as a dominant mutant for stabilizing SUMOylation. Cells were transfected with a donor plasmid with homology arms directed to the CCR5 locus (CCR5-TetON3G-mNeonPyS2-PuroR) and two gRNAs to target CCR5 locus. For the screening of the transgene integrated clones, primers were designed to amplify the 5' region (~3kb) and 3' region (~3.26kb) of the integration site. (B) After the selection using 1ug/mL Puromycin, 1 clone each per construct were further subjected to genomic PCR to confirm the integration of the transgene.
(C)
The whole cell lysates obtained from the candidate clones were subjected to Western Blotting to confirm the inducible expression of Py-S2 and Py-S2 Mut proteins. Anti-PIASy antibodies were used to detect expression of fusion proteins (+Dox) or not (-Dox), anti-H2A antibodies were used as a loading control. (D) The clone #79 was treated with auxin for 2, 4, and 6-hours, and evaluated the TopoIIα depletion by Western blotting. As a control, DLD-1 OsTIR1#50 parental cells were treated with auxin for 6 hours (DLD1 TIR1). Whole cell lysates were subjected to Western blotting analysis using indicated antibodies. Clone #79 was chosen for further analysis in the subsequent experiments showed in Figure 2 . (E) DLD-1 cells with endogenous TopoIIα tagged with an auxin inducible degron (AID) were synchronized in mitosis and treated with auxin 6 hours after Thymidine release. Cells were plated onto fibronectin coated coverslips and subsequently stained with anti-TopoIIα, anti-CENP-C, and DNA was labeled with DAPI. TopoIIα foci on mitotic chromosomes are completely eliminated with auxin treatment.
Supplemental
Supplemental Figure S5. Construction of PICH-AID cell line. (A)
Experimental schematic of donor plasmid used to tag the 5' end of endogenous PICH locus with AID tag. Cells were transfected with PICH-mAID-3xFlag-P2A-Hygromycin donor and two different guide RNAs. After selection with 400ug/mL hygromycin clones were isolated, whole cell lysates were collected from asynchronous populations, and Western blotting was performed. (B) Representative Western blot for hygromycin-resistant clone screening is shown. An anti-Flag antibody was used to detect AID-Flag tagged PICH (~180kDa) in the 700 channel (colored red) and anti-PICH antibodies were used to detect both AID-Flag tagged PICH (~180kDa) and untagged PICH (~150kDa) in the 800 channel (colored green). Non-transfected DLD-1 TIR1#50 parental cell line (labeled DLD-1) was used as a negative control. Anti-β-tubulin was used as a loading control. Among thirteen samples analyzed, the clones which showed a single yellow PICH band were chosen for genomic PCR analysis (clones #1, 6 and 11). (C) Genomic DNA was isolated and subjected to PCR using an F1 primer located upstream of the left homology arm and Hygro Rev PCR primer located within the insert. Non-transfected DLD-1 TIR#50 parental cell DNA was used as a control (DLD-1 NC).
(D)
The clones 1 and 6 were tested for further depletion of PICH protein by auxin addition at 4, 6, and 20hour time points. The non-transfected DLD-1 TIR1#50 parental cells were used as a control with either non-treated (TIR#50) or treated with auxin for 20 hours (TIR#50 +Aux 20 hours). The whole cell lysates were subjected to Western blotting analysis. Anti-PICH antibodies were used to detect PICH (~150kDa) or PICH-AID (~180kDa), anti-β-tubulin antibodies were used as a loading control. Clone #1 (marked in red) was chosen to utilize for subsequent experiments showed in Figure 5 and Figure S6 . (E) DLD-1 cells with endogenous PICH tagged with an auxin inducible degron (AID) were synchronized in mitosis and treated with DMSO or ICRF-193. Auxin was added 6 hours after Thymidine release. Mitotic cells obtained by shake-off were plated onto fibronectin coated coverslips and subsequently stained with indicated antibodies. DNA was labeled with DAPI. PICH foci on mitotic chromosomes were completely eliminated with auxin in both DMSO and ICRF-193 treated cells.
Supplemental Figure S6. Construction of Tet-inducible PICH mCherry mutants. (A)
Experimental schematic of donor plasmid used to introduce PICH mCherry mutants into the CCR5 safe harbor locus. Cells were transfected with PICH-mCherry-P2A-Zeocin donor and two different guide RNAs.
(B) After selection with 400ug/mL Zeocin clones were isolated, cells were treated with doxycycline and auxin for 14 hours, whole cell lysates were collected from asynchronous populations, and Western blotting was performed.
(C) Genomic DNA was isolated and subjected to PCR using a Sv40 F primer located within the insert and CCR5 Rev located outside of the right homology arm. Non-transfected DLD-1 TIR#50 parental cell DNA was used as a control (DLD-1 NC). (D) DLD-1 cells with endogenous PICH tagged with an auxin inducible degron (AID) and PICH mCherry mutants introduced into the CCR5 locus were synchronized in mitosis and treated with auxin and doxycycline for 22hours. Mitotic cells obtained by shake-off were plated onto fibronectin coated coverslips and subsequently stained with DAPI to label DNA and mCherry to label PICH expressing cells. 
